Federal Court Weighs Tighter Rules for Abortion Pill Mifepristone
A three-judge panel of the 5th U.S. Circuit Court of Appeals heard arguments on whether to tighten prescribing rules for mifepristone, a key component of the most common abortion method in the U.S. The case, brought by Louisiana's attorney general and a woman alleging coercion, is one of several efforts to block telehealth prescriptions of abortion pills across state lines. The FDA is also reviewing the rules, and the Supreme Court previously rejected a similar challenge in 2024 on standing grounds.
The case stems from a Louisiana lawsuit involving state Attorney General Liz Murrill and a woman alleging coercion. Prior rulings by lower courts and other 5th Circuit panels have deemed current mifepristone rules too permissive, though the Supreme Court previously dismissed a similar challenge on standing grounds.
Other Republican state attorneys general from Florida, Texas, Idaho, Kansas, and Missouri have filed separate lawsuits against FDA rules. Meanwhile, federal judges in Hawaii and Virginia have concluded the existing regulations are overly restrictive, highlighting a split in judicial opinions.
The outcome could affect access to medication abortion for women in restrictive states, particularly those relying on telehealth prescriptions from shield-law states. If the appeals court tightens rules, it may reduce the number of pills crossing state lines, potentially increasing travel burdens or reliance on in-person clinics. Conversely, FDA review could alter the landscape independently. The impact may hinge on whether courts prioritize state enforcement over federal agency authority.